U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO
Summarize this article with:
Renaissance Capital IPO Research7.4K FollowersFollow5ShareSavePlay(7min)CommentsSummaryThree IPOs and five SPACs priced this week.Six IPOs and two SPACs submitted initial filings.No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week.Street research is expected for two companies in the week ahead, and six lock-up periods will be expiring. DariaRen/iStock via Getty Images Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO atThis article was written byRenaissance Capital IPO Research7.4K FollowersFollowRenaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS). Individual investors can get a free overview of the IPO market on www.renaissancecapital.com, and try a free trial of our premium platform, IPO Pro (ipopro.renaissancecapital.com).
Through Renaissance Capital’s pre-IPO research service, institutional investors get an independent opinion, in-depth fundamental analysis, and customizable financial models on all IPOs.